Plain-English updates on where breast cancer research is headed - new drug approvals, earlier detection, and why funding research matters. This is what your donations make possible.
Breast cancer mortality in the U.S. has fallen by roughly 44% since 1989 - driven largely by research: better screening and better treatments.
Therapies are increasingly matched to the biology of each tumor - HER2, hormone receptors, gene mutations - meaning more effective treatment with fewer side effects.
Metastatic disease still has no cure, and diagnoses in younger women are rising. That's exactly where research funding goes to work.
Gedatolisib (Revtorpyk) was approved July 14, 2026 for hormone receptor-positive, HER2-negative breast cancer. It blocks three related pathways (PI3K/AKT/mTOR) that tumors rely on to keep growing - hitting cancer from more angles at once.
Vepdegestrant (Veppanu) is the first "PROTAC" therapy ever approved - a new kind of drug that tags cancer-driving proteins for destruction. It's an oral, once-daily option for ER-positive, HER2-negative breast cancer with an ESR1 mutation, a change that often helps tumors resist hormone therapy.
Sacituzumab govitecan (Trodelvy) is now approved as a first-line treatment for metastatic triple-negative breast cancer - either on its own or paired with immunotherapy, depending on the tumor. Triple-negative disease has historically had fewer targeted options, so an earlier-line approval is a meaningful shift.
Palbociclib is now approved alongside trastuzumab (with or without pertuzumab) and endocrine therapy as a maintenance treatment for HR-positive, HER2-positive metastatic breast cancer - giving patients another way to keep cancer controlled after initial treatment.
New national guidelines now call for AI-assisted mammogram risk assessment starting at age 35 - younger than standard screening typically begins - specifically to catch more cancers in younger women. In studies, AI reading mammograms alongside radiologists has caught more invasive cancers and cut false positives.
With diagnoses under 50 rising, researchers are investigating why - from genetics and dense tissue to lifestyle and environmental factors - and how screening guidelines should adapt. BCRF funds work specifically on early-onset breast cancer.
Note: summaries are for general education, not medical advice - always talk to your care team about treatment options. Sources worth following: BCRF research news and breastcancer.org research news.